Early gene-editing success holds promise for preventing inherited diseases

August 2, 2017, Salk Institute
Newly fertilized eggs before gene editing (left) and embryos after gene editing and a few rounds of cell division (right). Credit: OHSU/Mitalipov lab

Scientists have, for the first time, corrected a disease-causing mutation in early stage human embryos with gene editing. The technique, which uses the CRISPR-Cas9 system, corrected the mutation for a heart condition at the earliest stage of embryonic development so that the defect would not be passed on to future generations.

The work, which is described in Nature on August 2, 2017, is a collaboration between the Salk Institute, Oregon Health and Science University (OHSU) and Korea's Institute for Basic Science and could pave the way for improved in vitro fertilization (IVF) outcomes as well as eventual cures for some of the thousands of diseases caused by in single .

"Thanks to advances in stem cell technologies and gene editing, we are finally starting to address disease-causing mutations that impact potentially millions of people," says Juan Carlos Izpisua Belmonte, a professor in Salk's Gene Expression Laboratory and a corresponding author of the paper. "Gene editing is still in its infancy so even though this preliminary effort was found to be safe and effective, it is crucial that we continue to proceed with the utmost caution, paying the highest attention to ethical considerations."

Though gene-editing tools have the power to potentially cure a number of diseases, scientists have proceeded cautiously, in part to avoid introducing unintended mutations into the germ line ( that become eggs or sperm). Izpisua Belmonte is uniquely qualified to speak to the ethics of genome editing in part because, as a member of the committee on human gene editing of the National Academies of Sciences, Engineering and Medicine, he helped author the 2016 roadmap "Human Genome Editing: Science, Ethics, and Governance." The research in the current study is fully compliant with recommendations made in that document, and adheres closely to guidelines established by OHSU's Institutional Review Board and additional ad-hoc committees set up for scientific and ethical review.

Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden death in otherwise healthy young athletes, and affects approximately 1 in 500 people overall. It is caused by a dominant mutation in the MYBPC3 gene, but often goes undetected until it is too late. Since people with a mutant copy of the MYBPC3 gene have a 50 percent chance of passing it on to their own children, being able to correct the mutation in embryos would prevent the disease not only in affected children, but also in their descendants.

The researchers generated induced from a skin biopsy donated by a male with HCM and developed a gene-editing strategy based on CRISPR-Cas9 that would specifically target the mutated copy of the MYBPC3 gene for repair. The targeted mutated MYBPC3 gene was cut by the Cas9 enzyme, allowing the donor's cells' own DNA-repair mechanisms to fix the mutation during the next round of cell division by using either a synthetic DNA sequence or the non-mutated copy of MYBPC3 gene as a template.

Using IVF techniques, the researchers injected the best-performing gene-editing components into healthy donor eggs newly fertilized with the donor's sperm. Then they analyzed all the cells in the early embryos at single-cell resolution to see how effectively the mutation was repaired.

The scientists were surprised by just how safe and efficient the method was. Not only did a high percentage of embryonic cells get repaired, but also gene correction didn't induce any detectable off-target mutations and genome instability—major concerns for gene editing. In addition, the researchers developed a robust strategy to ensure the repair occurred consistently in all the cells of the embryo. (Spotty repairs can lead to some cells continuing to carry the mutation.)

"Even though the success rate in patient cells cultured in a dish was low, we saw that the seems to be very robust in embryos of which one copy of the MYBPC3 gene is mutated," says Jun Wu, a Salk staff scientist and one of the paper's first authors. This was in part because, after CRISPR-Cas9 mediated enzymatic cutting of the mutated , the embryo initiated its own repairs. Instead of using the provided synthetic DNA template, the team found, surprisingly, that the embryo preferentially used the available healthy copy of the gene to repair the mutated part. "Our technology successfully repairs the disease-causing gene mutation by taking advantage of a DNA repair response unique to early embryos" says Wu.

Izpisua Belmonte and Wu emphasize that, although promising, these are very preliminary results and more research will need to be done to ensure no unintended effects occur.

"Our results demonstrate the great potential of embryonic , but we must continue to realistically assess the risks as well as the benefits," adds Izpisua Belmonte.

Future work will continue to assess the safety and effectiveness of the procedure and efficacy of the technique with other mutations.

Explore further: Scientists repair gene defect in stem cells from patients with rare immunodeficiency

More information: Hong Ma et al. Correction of a pathogenic gene mutation in human embryos, Nature (2017). DOI: 10.1038/nature23305

Related Stories

Scientists repair gene defect in stem cells from patients with rare immunodeficiency

January 11, 2017
Scientists have developed a new approach to repair a defective gene in blood-forming stem cells from patients with a rare genetic immunodeficiency disorder called X-linked chronic granulomatous disease (X-CGD). After transplant ...

Gene-editing alternative corrects Duchenne muscular dystrophy

April 12, 2017
Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.

Scientists show how mutation causes incurable premature aging disease

October 31, 2016
Scientists have demonstrated how a mutation in a specific protein in stem cells causes an incurable premature aging disease called dyskeratosis congenita, and were able to introduce the mutation into cultured human cells ...

Premature cell differentiation leads to disorders in pancreatic development

April 11, 2017
Researchers at the University of Helsinki, Finland, have uncovered a mechanism through which a mutation in the STAT3 gene leads to a disorder in the development of the pancreas and to infant diabetes.

Recommended for you

Psychiatric disorders share an underlying genetic basis

June 21, 2018
Psychiatric disorders such as schizophrenia and bipolar disorder often run in families. In a new international collaboration, researchers explored the genetic connections between these and other disorders of the brain at ...

Deep data dive helps predict cerebral palsy

June 21, 2018
When University of Delaware molecular biologist Adam Marsh was studying the DNA of worms living in Antarctica's frigid seas to understand how the organisms managed to survive—and thrive—in the extremely harsh polar environment, ...

Genetic variation in progesterone receptor tied to prematurity risk, study finds

June 21, 2018
Humans have unexpectedly high genetic variation in the receptor for a key pregnancy-maintaining hormone, according to research led by scientists at the Stanford University School of Medicine. The finding may help explain ...

Shared genetics may shape treatment options for certain brain disorders

June 20, 2018
Symptoms of schizophrenia and bipolar disorder, including psychosis, depression and manic behavior, have both shared and distinguishing genetic factors, an international consortium led by researchers from Vanderbilt University ...

Scientists unravel DNA code behind rare neurologic disease

June 20, 2018
Scientists conducting one of the largest full DNA analyses of a rare disease have identified a gene mutation associated with a perplexing brain condition that blinds and paralyzes patients.

Simple sugar delays neurodegeneration caused by enzyme deficiency

June 20, 2018
A new therapeutic approach may one day delay neurodegeneration typical of a disease called mucopolysaccharidoses IIIB (MPS IIIB). Neurodegeneration in this condition results from the abnormal accumulation of essential cellular ...

4 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

EmceeSquared
not rated yet Aug 03, 2017
"Then they analyzed all the cells in the early embryos at single-cell resolution to see how effectively the mutation was repaired."

How does single-cell resolution show whether a single gene mutation like MH in MYBPC3 was repaired or not? The gene is thousands of times smaller than that resolution limit.
c0y0te
not rated yet Aug 03, 2017
@EmceeSquared
I might be wrong, but I understood that the single-cell resolution in this context meant that they have checked each cell one by one to see if the mutation was repaired. I guess they separated the cells (destroyed the embrio), and then sequenced the dna from each of them and checked it individually.
betterexists
not rated yet Aug 03, 2017
Scientists are ALWAYS capable of CREATING Identical Twins without any damage;
So, WHY NOT CREATE A Dog OR Cat Baby This Way and Another That way!
I mean 1 with Original Disease as usual and 1 without that ! IMAGINE How much progress can be made by this approach. Also, in Non-Original Mothers TOO !
EmceeSquared
not rated yet Aug 03, 2017
c0y0te:
the single-cell resolution in this context meant


Yes, I'd expect they'd have to do what you said. Evidently "single-cell resolution" means that they're sequencing only a single cell's (single) DNA, rather than collecting a lot of DNA.
https://www.ncbi.nlm.nih.gov/pubmed/27840107

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.